Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABLpositive chronic myeloid leukemia

Autophagy

Volumn 11, Issue 2, 2015, Pages 355-372

  Zeng, Xian ^a,b   Zhao, Hui ^a,c   Li, Yubin ^a   Fan, Jiajun ^a   Sun, Yun ^a   Wang, Shaofei ^a   Wang, Ziyu ^a   Song, Ping ^a   Ju, Dianwen ^a  

^a FUDAN UNIVERSITY   (China)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Autophagy; BCR ABL; CML; Drug resistance; Hedgehog pathway

Indexed keywords

AUTOPHAGY PROTEIN 5; AUTOPHAGY PROTEIN 7; BCR ABL PROTEIN; CASPASE 3; CASPASE 9; IMATINIB; SONIC HEDGEHOG PROTEIN; UNCLASSIFIED DRUG; VISMODEGIB; ANTINEOPLASTIC AGENT;

APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER RESISTANCE; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; ENZYME INHIBITION; GENE SILENCING; HUMAN; HUMAN CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN TARGETING; SIGNAL TRANSDUCTION; DRUG EFFECTS; DRUG RESISTANCE; K-562 CELL LINE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METABOLISM; MONONUCLEAR CELL; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HEDGEHOG PROTEINS; HUMANS; IMATINIB MESYLATE; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKOCYTES, MONONUCLEAR; SIGNAL TRANSDUCTION;

EID: 84943448617     PISSN: 15548627     EISSN: 15548635     Source Type: Journal    
DOI: 10.4161/15548627.2014.994368     Document Type: Article

References (62)

1. Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. Lancet 2007; 370:342-50; PMID:17662883; http://dx. doi. org/10. 1016/S0140-6736(07)61165-9
2. Jabbour E, Mathisen MS, O'Brien S. Ten years of progress in chronic myelogenous leukemia. J Natl Compr Canc Netw 2012; 10:1049-53; PMID:22956803
3. Kimura S, Ando T, Kojima K. Ever-advancing chronic myeloid leukemia treatment. Int J Clin Oncol 2014; 19:3-9; PMID:24258348; http://dx. doi. org/10. 1007/ s10147-013-0641-7
4. Briscoe J, Therond PP. The mechanisms of Hedgehog signalling and its roles in development and disease. Nat Rev Mol Cell Biol 2013; 14:416-29; PMID:24258348; http://dx. doi. org/10. 1038/nrm3598
5. Atwood SX, Chang AL, Oro AE. Hedgehog pathway inhibition and the race against tumor evolution. J Cell Biol 2012; 199:193-7; PMID:23071148; http://dx. doi. org/10. 1083/jcb. 201207140
6. Scales SJ, de Sauvage FJ. Mechanisms ofHedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci 2009; 30:303-12; PMID:19443 052; http://dx. doi. org/10. 1016/j. tips. 2009. 03. 007
7. Amakye D, Jagani Z, Dorsch M. Unraveling the therapeutic potential of the Hedgehog pathway in cancer. Nature Medicine 2013; 19:1410-22; PMID:24202394; http://dx. doi. org/10. 1038/nm. 3389
8. Merchant AA, Matsui W. Targeting Hedgehog-a cancer stem cell pathway. Clin Cancer Res 2010; 16:3130-40; PMID:20530699; http://dx. doi. org/10. 1158/ 1078-0432. CCR-09-2846
9. Dierks C, Grbic J, Zirlik K, Beigi R, Englund NP, Guo GR, Veelken H, Engelhardt M, Mertelsmann R, Kelleher JF, et al. Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat Med 2007; 13:944-51; PMID:17632527; http://dx. doi. org/ 10. 1038/nm1614
10. Low JA, de Sauvage FJ. Clinical experience with Hedgehog pathway inhibitors. J Clin Oncol 2010; 28:5321-6; PMID:21041712; http://dx. doi. org/ 10. 1200/JCO. 2010. 27. 9943
11. Mar BG, Amakye D, Aifantis I, Buonamici S. The controversial role of theHedgehog pathway in normal andmalignant hematopoiesis. Leukemia 2011; 25:1665-73; PMID: 21660044; http://dx. doi. org/10. 1038/leu. 2011. 143
12. Irvine DA, Copland M. Targeting hedgehog in hematologic malignancy. Blood 2012; 119:2196-204; PMID:22223823; http://dx. doi. org/10. 1182/blood-2011-10-383752
13. Jagani Z, Dorsch M, Warmuth M. Hedgehog pathway activation in chronic myeloid leukemia. Cell Cycle 2010; 9:3449-56; PMID:20928937; http://dx. doi. org/ 10. 4161/cc. 9. 17. 12945
14. Hamad A, Sahli Z, El Sabban M, Mouteirik M, Nasr R. Emerging therapeutic strategies for targeting chronic myeloid leukemia stem cells. Stem Cells Int 2013; 2013:724360; PMID:23935640; http://dx. doi. org/ 10. 1155/2013/724360
15. Queiroz KC, Ruela-de-Sousa RR, Fuhler GM, Aberson HL, Ferreira CV, Peppelenbosch MP, Spek CA. Hedgehog signaling maintains chemoresistance in myeloid leukemic cells. Oncogene 2010; 29:6314-22; PMID:208 02532; http://dx. doi. org/10. 1038/onc. 2010. 375
16. Dierks C, Beigi R, Guo G-R, Zirlik K, Stegert MR, Manley P, Trussell C, Schmitt-Graeff A, Landwerlin K, Veelken H, et al. Expansion of Bcr-Abl-Positive Leukemic Stem Cells Is Dependent on Hedgehog Pathway Activation. Cancer Cell 2008; 14:238-49; PMID:18772113; http://dx. doi. org/10. 1016/j. ccr. 2008. 08. 003
17. Warzecha J, Bonke L, Koehl U, Munkelt D, Gottig S, Percic D, Arabmotlagh M, Kurth A. The hedgehog inhibitor cyclopamine induces apoptosis in leukemic cells in vitro. Leuk Lymphoma 2008; 49:2383-6; PMID:19052992; http://dx. doi. org/10. 1080/ 10428190802510315
18. Kobune M, Takimoto R, Murase K, Iyama S, Sato T, Kikuchi S, Kawano Y, Miyanishi K, Sato Y, Niitsu Y, et al. Drug resistance is dramatically restored by hedgehog inhibitors in CD34+ leukemic cells. Cancer Sci 2009; 100:948-55; PMID:19245435; http://dx. doi. org/10. 1111/j. 1349-7006. 2009. 01111. x
19. Katagiri S, Tauchi T, Okabe S, Minami Y, Kimura S, Maekawa T, Naoe T, Ohyashiki K. Combination of ponatinib with Hedgehog antagonist vismodegib for therapy-resistant BCR-ABL1-positive leukemia. Clin Cancer Res 2013; 19:1422-32; PMID:23319824; http://dx. doi. org/10. 1158/1078-0432. CCR-12-1777
20. Swampillai AL, Salomoni P, Short SC. The role of autophagy in clinical practice. Clin Oncol (R Coll Radiol) 2012; 24:387-95; PMID:22032864; http://dx. doi. org/10. 1016/j. clon. 2011. 09. 010
21. Shanware NP, Bray K, Abraham RT. The PI3K, metabolic, and autophagy networks: interactive partners in cellular health and disease. Annu Rev Pharmacol Toxicol 2013; 53:89-106; PMID:23294306; http://dx. doi. org/10. 1146/annurev-pharmtox-010611-134717
22. Gewirtz DA. Cytoprotective and nonprotective autophagy in cancer therapy. Autophagy 2013; 9:1263-5; PMID:23800720; http://dx. doi. org/10. 4161/auto. 25233
23. Helgason GV, Karvela M, Holyoake TL. Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML. Blood 2011; 118:2035-43; PMID:21693757; http://dx. doi. org/10. 1182/ blood-2011-01-330621
24. Mishima Y, Terui Y, Taniyama A, Kuniyoshi R, Takizawa T, Kimura S, Ozawa K, Hatake K. Autophagy and autophagic cell death are next targets for elimination of the resistance to tyrosine kinase inhibitors. Cancer Sci 2008; 99:2200-8; PMID:18823378; http://dx. doi. org/10. 1111/j. 1349-7006. 2008. 00932. x
25. Bellodi C, Lidonnici MR, Hamilton A, Helgason GV, Soliera AR, Ronchetti M, Galavotti S, Young KW, Selmi T, Yacobi R, et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 2009; 119:1109-23; PMID:19363292; http://dx. doi. org/10. 1172/JCI35660
26. Nencioni A, Cea M, Montecucco F, Longo VD, Patrone F, Carella AM, Holyoake TL, Helgason GV. Autophagy in blood cancers: biological role and therapeutic implications. Haematologica 2013; 98:1335-43; PMID:24006406; http://dx. doi. org/10. 3324/haematol. 2012. 079061
27. Jimenez-Sanchez M, Menzies FM, Chang YY, Simecek N, Neufeld TP, Rubinsztein DC. The Hedgehog signalling pathway regulates autophagy. Nat Commun 2012; 3:1200; PMID:23149744; http://dx. doi. org/ 10. 1038/ncomms2212
28. Wang Y, Han C, Lu L, Magliato S, Wu T. Hedgehog signaling pathway regulates autophagy in human hepatocellular carcinoma cells. Hepatology 2013; 58:995-1010; PMID:23504944; http://dx. doi. org/10. 1002/ hep. 26394
29. Li H, Li J, Li Y, Singh P, Cao L, Xu LJ, Li D, Wang Y, Xie Z, Gui Y. Sonic hedgehog promotes autophagy of vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2012; 303:H1319-31; PMID:23023870; http://dx. doi. org/10. 1152/ajpheart. 00160. 2012
30. Petralia RS, Schwartz CM, Wang YX, Kawamoto EM, Mattson MP, Yao PJ. Sonic hedgehog promotes autophagy in hippocampal neurons. Biol Open 2013; 2:499-504; PMID:23789099; http://dx. doi. org/ 10. 1242/bio. 20134275
31. Sarkar FH, Li Y, Wang Z, Kong D. The role of nutraceuticals in the regulation of Wnt and Hedgehog signaling in cancer. Cancer and Metastasis Reviews 2010; 29:383-94; PMID:20711635; http://dx. doi. org/ 10. 1007/s10555-010-9233-4
32. Clevers H. Wnt/β-Catenin Signaling in Development and Disease. Cell 2006; 127:469-80; PMID: 17081971; http://dx. doi. org/10. 1016/j. cell. 2006. 10. 018
33. Sengupta A, Banerjee D, Chandra S, Banerji SK, Ghosh R, Roy R, Banerjee S. Deregulation and cross talk among Sonic hedgehog, Wnt, Hox and Notch signaling in chronic myeloid leukemia progression. Leukemia 2007; 21:949-55; PMID:17361218; http://dx. doi. org/10. 1038/sj. leu. 2404657
34. Zhao C, Blum J, Chen A, Kwon HY, Jung SH, Cook JM, Lagoo A, Reya T. Loss of β-Catenin Impairs the Renewal of Normal and CML Stem Cells In Vivo. Cancer Cell 2007; 12:528-41; PMID:18068630; http://dx. doi. org/10. 1016/j. ccr. 2007. 11. 003
35. Heidel Florian H, Bullinger L, Feng Z, Wang Z, Neff Tobias A, Stein L, Kalaitzidis D, Lane SW, Armstrong SA. Genetic and Pharmacologic Inhibition of β-Catenin Targets Imatinib-Resistant Leukemia Stem Cells in CML. Cell Stem Cell 2012; 10:412-24; PMID:22482506; http://dx. doi. org/10. 1016/j. stem. 2012. 02. 017
36. O'Hare T. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood 2004; 104:2532-9; PMID:15256422; http://dx. doi. org/ 10. 1182/blood-2004-05-1851
37. O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, Cowan-Jacob SW, Lee FY, Heinrich MC, Deininger MW, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005; 65:4500-5; PMID:15930265; http://dx. doi. org/10. 1158/0008-5472. CAN-05-0259
38. Yuan X, Zhang Y, Zhang H, Jin J, Li X, Liu H, Feng Z, Chen X. Activity of the potent dual Abl/Src tyrosine kinase inhibitor FB2 against Bcr-Abl positive cell lines in vitro and in vivo. Leuk Res 2011; 35:237-42; PMID:20739063; http://dx. doi. org/10. 1016/j. leukres. 2010. 07. 041
39. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012; 8:445-544; PMID:22966490; http://dx. doi. org/10. 4161/auto. 19496
40. Jung CH, Ro SH, Cao J, Otto NM, Kim DH. mTOR regulation of autophagy. FEBS Lett 2010; 584:1287-95; PMID:20083114; http://dx. doi. org/10. 1016/j. febslet. 2010. 01. 017
41. Ambjørn M, Ejlerskov P, Liu Y, Lees M, Jäättelä M, Issazadeh-Navikas S. IFNB1/interferon-β-induced autophagy in MCF-7 breast cancer cells counteracts its proapoptotic function. Autophagy 2013; 9:287-302; PMID:23221969; http://dx. doi. org/10. 4161/auto. 22831
42. Kawahara T, Kawaguchi-Ihara N, Okuhashi Y, Itoh M, Nara N, Tohda S. Cyclopamine and quercetin suppress the growth of leukemia and lymphoma cells. Anticancer Res 2009; 29:4629-32; PMID:20032413
43. Kim JE, Yoon S, Choi BR, Kim KP, Cho YH, Jung W, Kim DW, Oh S, Kim DE. Cleavage of BCR-ABL transcripts at the T315I point mutation by DNAzyme promotes apoptotic cell death in imatinib-resistant BCRABL leukemic cells. Leukemia 2013; 27:1650-8; PMID:23434731; http://dx. doi. org/10. 1038/ leu. 2013. 60
44. Shi X, Jin Y, Cheng C, Zhang H, ZouW, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. Clin Cancer Res 2009; 15:1686-97; PMID:19240172; http://dx. doi. org/10. 1158/1078-0432. CCR-08-2141
45. Weiner LM, Lotze MT. Tumor-cell death, autophagy, and immunity. N Engl J Med 2012; 366:1156-8; PMID:22435376; http://dx. doi. org/10. 1056/ NEJMcibr1114526
46. Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell 2011; 147:728-41; PMID: 22078875; http://dx. doi. org/10. 1016/j. cell. 2011. 10. 026
47. Choi AMK, Ryter SW, Levine B. Autophagy in human health and disease. N Engl J Med 2013; 368:651-62; PMID:23406030; http://dx. doi. org/10. 1056/ NEJMra1205406
48. Janku F, McConkey DJ, Hong DS, Kurzrock R. Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol 2011; 8:528-39; PMID:21587219; http:// dx. doi. org/10. 1038/nrclinonc. 2011. 71
49. Rosenfeld MR, Ye X, Supko JG, Desideri S, Grossman SA, Brem S, Mikkelson T, Wang D, Chang YC, Hu J, et al. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy 2014; 10:1359-68; PMID:24991840; http://dx. doi. org/ 10. 4161/auto. 28984
50. Rangwala R, Leone R, Chang YC, Fecher L, Schuchter L, Kramer A, Tan KS, Heitjan DF, Rodgers G, Gallagher M, et al. Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy 2014; 10:1369-79; PMID:24991839; http://dx. doi. org/10. 4161/auto. 29118
51. Vogl DT, Stadtmauer EA, Tan KS, Heitjan DF, Davis LE, Pontiggia L, Rangwala R, Piao S, Chang YC, Scott EC, et al. Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma. Autophagy 2014; 10:1380-90; PMID:24991834; http://dx. doi. org/10. 4161/auto. 29264
52. Rangwala R, Chang YC, Hu J, Algazy KM, Evans TL, Fecher LA, Schuchter LM, Torigian DA, Panosian JT, Troxel AB, et al. Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. Autophagy 2014; 10:1391-402; PMID:24991838; http://dx. doi. org/10. 4161/ auto. 29119
53. Mahalingam D, Mita M, Sarantopoulos J, Wood L, Amaravadi R, Davis LE, Mita AC, Curiel TJ, Espitia CM, Nawrocki ST, et al. Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors. Autophagy 2014; 10:1403-14; PMID:24991835; http://dx. doi. org/10. 4161/ auto. 29231
54. Barnard RA, Wittenburg LA, Amaravadi RK, Gustafson DL, Thorburn A, Thamm DH. Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma. Autophagy 2014; 10:1415-25; PMID:24991836; http://dx. doi. org/10. 4161/auto. 29165
55. Gao J, Graves S, Koch U, Liu S, Jankovic V, Buonamici S, El Andaloussi A, Nimer SD, Kee BL, Taichman R, et al. Hedgehog signaling is dispensable for adult hematopoietic stem cell function. Cell Stem Cell 2009; 4:548-58; PMID:19497283; http://dx. doi. org/ 10. 1016/j. stem. 2009. 03. 015
56. Hofmann I, Stover EH, Cullen DE, Mao J, Morgan KJ, Lee BH, Kharas MG, Miller PG, Cornejo MG, Okabe R, et al. Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis. Cell Stem Cell 2009; 4:559-67; PMID: 19497284; http://dx. doi. org/10. 1016/j. stem. 2009. 03. 016
57. Wang Y, Ding Q, Yen CJ, Xia W, Izzo JG, Lang JY, Li CW, Hsu JL, Miller SA, Wang X, et al. The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell 2012; 21:374-87; PMID:22439934; http://dx. doi. org/ 10. 1016/j. ccr. 2011. 12. 028
58. Goussetis DJ, Gounaris E, Wu EJ, Vakana E, Sharma B, Bogyo M, Altman JK, Platanias LC. Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide. Blood 2012; 120:3555-62; PMID:22898604; http:// dx. doi. org/10. 1182/blood-2012-01-402578
59. Zhai B, Hu F, Jiang X, Xu J, Zhao D, Liu B, Pan S, Dong X, Tan G, Wei Z. Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma. Mol Cancer Ther 2014; 13:1589-98; PMID:24705351; http://dx. doi. org/10. 1158/1535-7163. MCT-13-1043
60. Zeng X, Li Y, Fan J, Zhao H, Xian Z, Sun Y, Wang Z, Wang S, Zhang G, Ju D. Recombinant human arginase induced caspase-dependent apoptosis and autophagy in non-Hodgkin's lymphoma cells. Cell Death Dis 2013; 4:e840; PMID:24113174; http://dx. doi. org/10. 1038/ cddis. 2013. 359
61. Li Y, Zhu H, Zeng X, Fan J, Qian X, Wang S, Wang Z, Sun Y, Wang X, Wang W, et al. Suppression of autophagy enhanced growth inhibition and apoptosis of interferon-beta in human glioma cells. Mol Neurobiol 2013; 47:1000-10; PMID:23329343; http://dx. doi. org/10. 1007/s12035-013-8403-0
62. Fan J, Zeng X, Li Y, Wang S, Wang Z, Sun Y, Gao H, Zhang G, Feng M, Ju D, et al. Autophagy plays a critical role in ChLym-1-induced cytotoxicity of nonhodgkin's lymphoma cells. PLoS One 2013; 8:e72478; PMID:24015249; http://dx. doi. org/10. 1371/journal. pone. 0072478